185 related articles for article (PubMed ID: 10663384)
21. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
22. In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais.
Peamkrasatam S; Sriwatanakul K; Kiyotani K; Fujieda M; Yamazaki H; Kamataki T; Yoovathaworn K
Drug Metab Pharmacokinet; 2006 Dec; 21(6):475-84. PubMed ID: 17220563
[TBL] [Abstract][Full Text] [Related]
23. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.
Xu C; Rao YS; Xu B; Hoffmann E; Jones J; Sellers EM; Tyndale RF
Biochem Biophys Res Commun; 2002 Jan; 290(1):318-24. PubMed ID: 11779172
[TBL] [Abstract][Full Text] [Related]
24. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
25. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).
Kiyotani K; Yamazaki H; Fujieda M; Iwano S; Matsumura K; Satarug S; Ujjin P; Shimada T; Guengerich FP; Parkinson A; Honda G; Nakagawa K; Ishizaki T; Kamataki T
Pharmacogenetics; 2003 Nov; 13(11):689-95. PubMed ID: 14583682
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism.
Oscarson M
Drug Metab Dispos; 2001 Feb; 29(2):91-5. PubMed ID: 11159795
[TBL] [Abstract][Full Text] [Related]
28. Characterization of liver microsomal 7-ethoxycoumarin O-deethylation and chlorzoxazone 6-hydroxylation activities in Japanese and Caucasian subjects genotyped for CYP2E1 gene.
Inoue K; Yamazaki H; Shimada T
Arch Toxicol; 2000 Sep; 74(7):372-8. PubMed ID: 11043492
[TBL] [Abstract][Full Text] [Related]
29. Variation in coumarin 7-hydroxylase activity associated with genetic polymorphism of cytochrome P450 2A6 and the body status of iron stores in adult Thai males and females.
Ujjin P; Satarug S; Vanavanitkun Y; Daigo S; Ariyoshi N; Yamazaki H; Reilly PE; Moore MR; Kamataki T
Pharmacogenetics; 2002 Apr; 12(3):241-9. PubMed ID: 11927840
[TBL] [Abstract][Full Text] [Related]
30. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes.
Yamazaki H; Inoue K; Hashimoto M; Shimada T
Arch Toxicol; 1999 Mar; 73(2):65-70. PubMed ID: 10350185
[TBL] [Abstract][Full Text] [Related]
31. CYP2A6: a human coumarin 7-hydroxylase.
Pelkonen O; Rautio A; Raunio H; Pasanen M
Toxicology; 2000 Apr; 144(1-3):139-47. PubMed ID: 10781881
[TBL] [Abstract][Full Text] [Related]
32. Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes.
Li Y; Li NY; Sellers EM
Eur J Drug Metab Pharmacokinet; 1997; 22(4):295-304. PubMed ID: 9512924
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
[TBL] [Abstract][Full Text] [Related]
34. Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies.
Soucek P
Arch Biochem Biophys; 1999 Oct; 370(2):190-200. PubMed ID: 10510277
[TBL] [Abstract][Full Text] [Related]
35. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
36. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
[TBL] [Abstract][Full Text] [Related]
38. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
39. Functional Characterization of 34 CYP2A6 Allelic Variants by Assessment of Nicotine C-Oxidation and Coumarin 7-Hydroxylation Activities.
Hosono H; Kumondai M; Maekawa M; Yamaguchi H; Mano N; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Dispos; 2017 Mar; 45(3):279-285. PubMed ID: 27974382
[TBL] [Abstract][Full Text] [Related]
40. [Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese].
Yokoi T; Kamataki T
Nihon Yakurigaku Zasshi; 1998 Jul; 112(1):5-14. PubMed ID: 9755457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
